AGP Executive Report
Last update: 10 hours agoProstate Cancer Diagnostics: ProsTIC26 highlighted PRIMARY2, using PSMA PET to better manage men with equivocal mpMRI (PI-RADS 2–3) and persistent risk, aiming to reduce unnecessary biopsies. Risk Stratification in Prostate Cancer: Another ProsTIC26 talk mapped how PSMA PET could refine D’Amico-style risk groups and “very-high-risk” categories for more tailored care. Next-Gen Prostate Theranostics: ProsTIC26 also focused on Lu-PSMA combination strategies to overcome resistance, weighing options like AR pathway inhibitors, chemo, T-cell engagers, antibody-drug conjugates, and DDR inhibitors. Menopause & Misinformation: Xand van Tulleken’s investigation targets the menopause supplement boom, arguing social media and fear around HRT have fueled risky “HRT alternatives.” Nigeria Pharma Policy: NAFDAC says its “5+5” and Ceiling List rules are boosting local drug manufacturing and cutting import dependence. Heart Failure Research: A gut-bacteria compound from pomegranates/walnuts (urolithin A) improved HFpEF heart function in models, but human trials are still needed. Cancer Care Tech: ORFAN-MAESTRIA reports AI can predict cardioembolic stroke and atrial fibrillation from routine cardiac CT scans. Drug Safety: India warns about suspected counterfeit Abhayrab rabies vaccine batches, urging dose verification. Mental Health & Sports: Reviews link pickleball to better wellbeing and padel to confidence/anxiety effects, while studies also explore loneliness, nightmares, and AI companions’ mixed impacts.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
